Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10269463 | 0.89 | LMNA (0.38) | ALDH1A1TDP1FFAR3LCKFYN | |
| SCHEMBL6134171 | 0.85 | — | — | |
| SCHEMBL11949568 | 0.83 | MGAM (0.48) | ALDH1A1LMNAMGAMGAASI | |
| SCHEMBL16609885 | 0.81 | — | — | |
| SCHEMBL14945716 | 0.79 | — | — | |
| SCHEMBL454918 | 0.78 | — | — | |
| SCHEMBL11554744 | 0.75 | CES2 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL1286839 | 0.69 | LMNA (0.35) | ALDH1A1FFAR3LCKFYNLMNA | |
| SCHEMBL686322 | 0.69 | — | — | |
| SCHEMBL14998106 | 0.69 | ALDH1A1 (0.50) | ALDH1A1TDP1TRPA1CA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101340893-B | Intranasal administration of rapid acting insulin | NASTECH PHARM CO | 2012-03-21 | — | — | CN | disclosed |
| CN-102046021-A | Film coated compressed chewing gum | FERTIN PHARMA AS | 2011-05-04 | — | — | CN | disclosed |
| US-20100080843-A1 | Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis | The Research Foundation of the State University Of New York at Albany (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100080843-A1 | Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis | The Research Foundation of the State University Of New York at Albany (US) | 2010-04-01 | — | — | US | disclosed |
| CN-101340893-A | Intranasal administration of rapid acting insulin | NASTECH PHARM CO (US) | 2009-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080843-A1 | Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis | SCLY, SELE, GPX1 | ALDH1A1 1027/4885TDP1 3998/4885FFAR3 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.